Eli Lilly Retatrutide Early Access: Who Qualifies and How Your Doctor Applies

By The RX Index Editorial Team · Last verified October 14, 2026

Eli Lilly's retatrutide early access is real, but narrow. In the U.S., your treating doctor can request it for certain adults with BMI 35+ and at least two serious obesity-related conditions under treatment. All five rules must be met, including treatment-history and trial-access requirements. Retatrutide is not FDA-approved. Lilly supplies the drug free; other care may cost extra.

Here's the catch: there are five rules, not just a BMI cutoff. And your doctor has to take on real paperwork and monitoring, because Lilly won't ship it to you. Use the check below to prepare that conversation.

RX Index Decision Verdict: Start with the doctor who treats your weight, not a checkout page.

• Best for: adults with severe obesity whose response to the highest available dose of an approved weight-management medicine has not been enough, despite taking and tolerating it as prescribed.
• Not ideal for: anyone hoping for a normal prescription, a faster route to more weight loss, or a spot in line.
• The factor that matters most: your full medical record — and a doctor willing to run the request.

Check what to bring to your doctor

This quick check walks you through Lilly's five rules one at a time. It won't tell you that you qualify. Your doctor and Lilly must review your medical history, and FDA and ethics-board requirements still apply. What it will do is organize your answers and open questions into a packet for your doctor.

Subject: Could we review retatrutide expanded access?

I read about Lilly's retatrutide expanded access program (registry record NCT07629401). Could we review whether its five published requirements might apply to me?

I'd like to go over my current BMI, my treatment history and how I've responded, the conditions I'm being treated for, any trial options, and the other treatments we've discussed, including surgery. I understand a checklist isn't approval.

Could your practice manage an investigational drug request and the monitoring it needs, or help me find a team that can? Before we start, I'd also like to understand any costs for visits, tests, ethics review, or travel. What should our plan be while this is considered?

A quick example (made up, to show how it works): Say you're 52, 5'6", and 230 pounds. That's a BMI of about 37.1. You've been on the highest available dose of Zepbound for nine months, you take it as prescribed, and your weight stalled. You use a CPAP machine for sleep apnea and take two blood pressure pills. No retatrutide trial near you is enrolling, and your doctor walked you through surgery as an option. That's a useful history to bring — not proof that you meet all five rules. Your doctor still needs to assess your treatment response and tolerance, whether both conditions meet the seriousness requirement, and whether a comparable trial is workable. A plateau and two prescriptions don't answer those questions.

Who qualifies for Lilly's retatrutide early access?

Lilly's official program record, NCT07629401, lists five rules, and a patient must meet all of them. Anyone with a medical reason they shouldn't take retatrutide is excluded. Your doctor can raise a possible case with Lilly; meeting the published rules does not guarantee access. Lilly still reviews each request one by one.

Lilly calls this "expanded access." It's the FDA's term for getting an unapproved drug outside a clinical trial. You'll also hear it called "compassionate use." "Early access" is the news headline version. On this page, those names refer to this specific Lilly program.

Source: ClinicalTrials.gov NCT07629401 and Lilly Medical, checked October 14, 2026.

BMI means body mass index — a number from your height and weight. Refractory obesity means obesity that hasn't come down enough despite the treatment the rule describes. The public criteria do not give a minimum time on treatment or a weight-loss cutoff, so we won't invent one.

Why we show all five rules

A shortened news list is not the full set of requirements. The official record lists all five, including the talk about all standard options and surgery. If your doctor is reading a news story, hand them the record instead.

What if I couldn't handle the highest dose?

The rule says "adherence to and tolerance of" the highest available dose. That's stricter than "the highest dose I could tolerate." If side effects kept you on a lower dose, don't change anything on your own to fit a website checklist. Ask your doctor to raise your exact history with Lilly. Lilly decides how it reads your record.

Do I have to have weight-loss surgery first?

No. The rule is that you've discussed surgery and other standard options with your doctor. That's called shared decision-making: you and your doctor go over the choices together and pick a plan. You don't have to have surgery or agree to it.

What counts as a "serious" condition?

The public program documents don't name a list of automatically qualifying diagnoses. That's a decision for your doctor and Lilly. A diagnosis such as sleep apnea or high blood pressure does not, by itself, establish that the condition meets this program's seriousness requirement. Bring the records showing how serious each condition is and how it is being treated.

The honest truth is that wanting more weight loss isn't enough to meet these rules. That isn't a dead end. The right GLP-1 path for you depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medicine, a shot or a pill, and your budget. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows suggested paths and providers to compare — free, about 2 minutes, no signup. It doesn't apply for retatrutide or check your plan's actual coverage. Compounded medicines are not FDA-approved.

Is Lilly's early access program real?

Yes. Lilly posted the program to the federal trial registry on June 5, 2026, and on August 3, 2026 told reporters it is reviewing requests from health care providers. It's a case-by-case exception for a small group of patients, not a launch or a waitlist.

Here's how it unfolded:

You may see something that looks like a contradiction. Lilly's public retatrutide FAQ, updated September 2026, still says retatrutide is legally available only through Lilly's clinical trials. Lilly's own professional page and the registry record describe the expanded access route. We're showing you both so you're not caught off guard. The professional page and the record are the documents about this program.

One more thing we can't tell you: how many people Lilly has said yes to. The program documents we checked do not give a total. They also do not give patient-specific approval odds.

How does your doctor apply for retatrutide early access?

Your treating doctor — not you — starts the request by calling the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). If your information fits, Lilly sends a detailed intake form and reviews the case. If Lilly agrees, your doctor files with the FDA, gets an ethics board's approval, and you sign a consent form before the first dose.

Lilly's record says patients and caregivers should go to their own doctor, not call Lilly. So the first move is yours: book the visit.

Here's who does what:

Sources: Lilly Medical; FDA, how physicians request single-patient expanded access; FDA, information for physicians. Checked October 14, 2026.

Lilly doesn't ship the drug to patients. It goes to your doctor.

Lilly is the first gate, not the only one

Think of it like renting an apartment. The landlord has to agree to hand over the keys. But the city's safety rules still matter.

Here, Lilly is the landlord. The FDA says it allows over 99% of the single-patient expanded access requests it receives to proceed. That figure covers many investigational drugs; it is not your chance of getting retatrutide. No law makes a company supply its drug. Without Lilly's yes, nothing moves — and FDA and ethics-board requirements still apply. (FDA)

How long does it take?

Lilly says it responds within five business days after it has the request and the medical information it needs. That's a response, not an approval. For a non-emergency single-patient FDA request, treatment may begin 30 days after FDA receives it, or sooner if FDA permits, unless FDA places it on clinical hold. Required ethics review and consent must also be complete. Thirty days is not a promised total wait from your first call. (Lilly; FDA)

In its August 3 report, STAT said doctors had sent requests without yet receiving a reply. The public program documents we checked do not give an average end-to-end wait. (STAT)

Can my doctor really take this on?

Your doctor needs the setup to manage an investigational medicine, not just write a prescription. Under Lilly's terms, your doctor becomes responsible for the drug's storage, handing it out, returns, an ethics board, and safety reports. A busy primary-care office may not be set up for that. Ask whether a hospital-based obesity clinic or an office that runs research could help. If your doctor can't, ask who in your area can.

Your doctor also needs current trial information. The dated trial table below is a starting point; the study team must confirm screening at a specific site.

Can a telehealth doctor apply?

The record says the request comes from the treating physician, and Lilly says the doctor has to be committed to the treatment. The physician must take responsibility for your care under the program. Whether a particular online practice can handle the storage, ethics board, and reporting is a question for that practice — and Lilly decides.

What to send your doctor

Copy this into your patient portal or bring it to your visit:

Subject: Could we review retatrutide expanded access? I read about Lilly's retatrutide expanded access program (registry record NCT07629401). Could we review whether its five published requirements might apply to me? I'd like to go over my current BMI, my treatment history and how I've responded, the conditions I'm being treated for, any trial options, and the other treatments we've discussed, including surgery. I understand a checklist isn't approval. Could your practice manage an investigational drug request and the monitoring it needs, or help me find a team that can? Before we start, I'd also like to understand any costs for visits, tests, ethics review, or travel. What should our plan be while this is considered?

This is a conversation starter we wrote. It isn't a Lilly form, an FDA filing, or a statement that you meet any rule.

How much does retatrutide early access cost?

Lilly says it provides the drug itself at no cost through this program. Everything around the drug — visits, lab tests, monitoring, an ethics board review, and travel — is a separate question. FDA warns that costs tied to expanded access are often not covered by insurance. Ask for those costs before you start.

Think of it like a free concert ticket. The ticket is free. Parking, gas, and the drive can still cost you.

Sources: Lilly Medical; FDA, information for patients. Checked October 14, 2026.

Federal rules back this up in another way. For the drug in an individual-patient expanded access request, a sponsor needs FDA's written permission to charge and may recover only the permitted direct costs (21 CFR 312.8). Lilly says it isn't charging for the drug.

Say your doctor's office confirms the drug is free, but hasn't priced the visits or labs yet. Your estimate isn't $0. It's "not finished." One question gets you the real picture: "What could I owe if Lilly says no, and what costs start only if treatment goes ahead?"

Retatrutide is not on the current Medicare GLP-1 Bridge product list. That list does not decide which other medical services your own plan might cover. For the post-approval picture, see whether retatrutide will be covered by the CMS BALANCE model and our retatrutide cost predictions.

Is a retatrutide trial open instead?

As of October 14, 2026, our ClinicalTrials.gov search for Lilly studies of retatrutide marked Recruiting, Not yet recruiting, or Enrolling by invitation returned one study: SYNERGY-Outcomes. It's a liver-disease study that lasts about 4.5 years and may give placebo. The other trial rows are closed to new enrollment; expanded access is a separate process. A registry label does not guarantee a local screening slot.

This matters for rule 4. If no retatrutide or comparable investigational-drug trial is workable, that's part of what your doctor documents.

To ask about SYNERGY-Outcomes, use Lilly's official study page or the trial contact listed in the registry: 1-877-CTLILLY (1-877-285-4559). Three questions worth asking: Is a site near me screening new patients now? Which treatments could I be assigned? What does my doctor need to review before I make plans?

Trials have their own rules. TRIUMPH-7, for example, excluded people who'd taken weight-loss drugs in the 90 days before screening. Never stop a prescribed medicine to chase a trial spot without your prescriber and the study team. For the broader access picture, see our retatrutide availability guide. For current study records, search the official registry.

What early access doesn't mean

Early access isn't FDA approval, and it doesn't give you a launch date or a pharmacy price. It also has nothing to do with "retatrutide" sold online: FDA says retatrutide cannot be compounded under U.S. federal law, and a "research use only" label does not establish that a vial is authentic Lilly supply.

It's not approval. Retatrutide is still investigational. Lilly said on July 23, 2026 that it plans to ask the FDA for approval in the first quarter of 2027 (Lilly). That is a planned filing, not FDA approval or a promised launch date. Lilly says the early access program ends once the drug is approved and on the market. For the wider availability question, see our retatrutide availability guide.

It's not "reta" from a website. The FDA states that retatrutide cannot be used in compounding under federal law, and it has warned telehealth companies, ingredient sellers, and outsourcing facilities over retatrutide. On August 12, 2026, Lilly announced six lawsuits against sellers it alleges illegally marketed retatrutide, including under "research use only" claims. Those are Lilly's allegations, not court findings. Paying an online clinic doesn't get you into Lilly's program. The documented process starts with your treating physician and still requires the program's reviews.

If you've used something labeled retatrutide and feel unwell, call your doctor. If someone collapses, has a seizure, has trouble breathing, or can't be awakened, call 911 now. For other suspected poisonings or questions about an unknown product, call Poison Control at 1-800-222-1222. Keep the label and packaging for the care team. (Poison Control) Our guide to spotting fake GLP-1 medicines covers the warning signs.

What to do if early access doesn't fit you

Not fitting Lilly's rules doesn't mean you're out of options. FDA-approved medicines are available to discuss with your clinician, and using one doesn't stop you from asking about retatrutide later. Using a weight-loss medicine can affect trial screening, so keep those questions with your prescriber. The right next step depends on where you are now.

If you're comparing other treatment paths with your clinician, the same short quiz from earlier can help sort provider options by how you want to pay and your preferences.

If private-insurance costs are what's stopping you from discussing an FDA-approved option, check before you assume the answer is no. Ro's free coverage check is separate from its paid treatment program. It looks at Ozempic, Wegovy, and Zepbound pens and sends a report by email after you provide your name, insurance-card details, and eligibility information. It does not prescribe or submit a request for treatment. It does not currently check the Wegovy pill, Foundayo pill, or Zepbound KwikPen. (Ro's checker)

If you later join Ro Body and a clinician prescribes, its insurance team can handle prior-authorization paperwork — prior authorization is your insurer's review before agreeing to cover a medicine. The insurer can still say no. Ro says its membership fee is not covered by insurance. Its published price is $39 for the first month, refunded if you're not eligible for treatment, then $149 on the monthly plan, or $74 a month as a 12-month equivalent paid annually — $888 for that prepaid term. Other prepaid plans sit between those rates. Medication is billed separately whether you use insurance or pay cash. Ro says its brand cash prices match LillyDirect, NovoCare, and TrumpRx; that is Ro's claim, not an independent price comparison we performed. (Pricing; insurance terms, checked October 14, 2026.)

The $888 term is not a pay-monthly offer. Ro's terms say cancellation prevents future renewals and fees generally are not refundable except under stated exceptions; don't assume unused prepaid months will be refunded. Medicare, TRICARE, and Medicaid coverage questions belong with your own plan and prescriber first. The button below starts the free coverage check, not a paid intake or a retatrutide request.

What we actually verified

We checked the medical access rules against Lilly's, FDA's, and ClinicalTrials.gov's own documents on October 14, 2026. Where two official sources disagree, we show both. Historical reporting is labeled as reporting, not medical evidence. We didn't contact Lilly, apply for the program, call study sites, or use any retatrutide product.

Checked October 14, 2026:

• The program record NCT07629401: status, five rules, exclusion, request instructions (first posted June 5, 2026; last update posted August 6, 2026)
• Lilly Medical's retatrutide expanded access page: no-cost drug, physician duties, no direct shipping, end of program (last reviewed by Lilly August 26, 2026)
• Lilly's expanded access policy: five-business-day response, regulator approval before shipping
• FDA pages for physicians and patients, and 21 CFR 312.8
• The FDA's unapproved GLP-1 page: current displayed retatrutide compounding and safety statements
• Lilly's study pages for SYNERGY-Outcomes, TRIUMPH-7, and TRIUMPH-9, plus official registry records for those studies and TRIUMPH-Outcomes. SYNERGY's last posted registry update was October 8, 2026. The scoped registry search returned one recruiting study, not a guarantee of local screening or treatment assignment.
• Ro's pricing, free coverage checker, insurance page, and payment terms — published terms, not prices we paid or a coverage report we obtained
• CMS's current Bridge product list; Lilly's July 23 filing plan and August 12 lawsuit announcement
• CDC's BMI formula and the example's arithmetic; Poison Control's emergency guidance; our live Find My GLP-1 Path entry page and its public description

Source conflict: Lilly's public FAQ still says trials only; the program record and Lilly's professional page describe expanded access.

What we couldn't confirm: how many requests Lilly has approved; whether any individual will be accepted; total costs for visits, tests, and review; how long an individual gets the drug; whether a given trial site is screening this week; or your insurer's answer. The worksheet organizes self-reported answers, not clinical findings.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Read how we evaluate.

Retatrutide early access FAQ

Can I get retatrutide without joining a trial?

Possibly, through Lilly's expanded access program, but only in narrow cases. You need to meet all five published rules, your treating doctor has to request it, and Lilly decides case by case. It's not routine prescribing.

Does early access mean FDA approval is close?

No. Early access for one patient and approval for everyone are separate decisions. Lilly's July 23, 2026 announcement set out a plan to file in the first quarter of 2027. That planned filing does not establish an approval date or commercial launch.

Who qualifies for Lilly's retatrutide early access?

Adults 18+ with a BMI of 35 or more despite sticking with and tolerating the highest available dose of a weight-management medicine, two or more serious weight-related conditions receiving standard care, no workable retatrutide or comparable trial, and a documented talk about all options including surgery. A medical reason not to take retatrutide rules you out.

Can I apply myself or join a waitlist?

No. The request has to come from your treating doctor, who calls the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). The published program is not a patient signup or public waitlist.

Is retatrutide early access free?

Lilly says it provides the drug at no cost. Visits, lab tests, monitoring, ethics board review, and travel aren't covered by that statement, and FDA warns that related care costs are often not covered by insurance. Ask your doctor's office for a cost estimate first.

Does meeting the BMI rule mean I qualify?

No. BMI is one part of rule 2, and there are four other rules plus an exclusion. Lilly still reviews every request.

What if my doctor can't manage the request?

Ask whether another doctor or clinic can. Under Lilly's terms, the doctor files with the FDA, gets an ethics board's approval, stores and hands out the drug, and reports side effects. Ask whether a clinic that already runs research can help; its ability to take your case still needs to be confirmed.

Do I have to stop my current weight-loss medicine?

Don't change any medicine on your own. Rule 2 includes your BMI and treatment response despite taking and tolerating the highest available dose as prescribed. Trials are different — some exclude recent weight-loss drug use — so any change should be planned with your prescriber and the study team.

How long does it take?

Lilly says it responds within five business days after it has the request and required medical information. For a non-emergency FDA request, treatment may start after 30 days or earlier permission, unless FDA places it on clinical hold; required ethics review and consent must also be complete. Neither clock promises how long the whole process will take.

Is online "reta" the same as Lilly's early access?

No. FDA says retatrutide cannot be used in compounding under U.S. federal law, and a research-use label is not proof of authentic Lilly supply. Lilly's expanded access process supplies the treating care team, not the patient directly.

Can I get early access outside the U.S.?

Outside the U.S., doctors contact their local Lilly office, and that country's regulator must approve before Lilly ships. The five rules here are on the U.S. record, so don't assume they're the same elsewhere.

How long would I keep getting it?

The public program documents do not promise an individual treatment duration. Lilly says expanded access ends after potential FDA approval and commercial availability. Ask your doctor what follow-up and transition plan would apply to you.

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Sources

Checked October 14, 2026. Dates in parentheses belong to the source, not this page. STAT's accessible original reporting is used only for the labeled history, not as proof of medical eligibility or safety.

1. ClinicalTrials.gov — Pre-approval Expanded Access of Retatrutide (LY3437943), NCT07629401 (first posted June 5, 2026; last update posted August 6, 2026).
2. Lilly Medical — Is there an expanded access program for retatrutide? (last reviewed August 26, 2026).
3. Eli Lilly — Expanded Access policy.
4. FDA — For Physicians: How to Request Single Patient Expanded Access.
5. FDA — Expanded Access: Information for Physicians.
6. FDA — Expanded Access: Information for Patients.
7. eCFR — 21 CFR 312.8, Charging for investigational drugs.
8. FDA — Concerns with unapproved GLP-1 drugs used for weight loss.
9. Eli Lilly — What to know about retatrutide (updated September 2026; its trials-only wording conflicts with the specific expanded-access documents).
10. Eli Lilly — Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026).
11. Eli Lilly — Announcement of six retatrutide-related lawsuits (August 12, 2026; manufacturer allegations).
12. Lilly Trials — SYNERGY-Outcomes, TRIUMPH-7, TRIUMPH-9.
13. ClinicalTrials.gov — NCT07165028 (updated October 8, 2026), NCT07035093 (updated September 25, 2026), NCT07357415 (updated June 9, 2026), NCT06383390 (updated October 8, 2026).
14. STAT — Original compassionate-access report (June 23, 2026; accessible opening reports an April request for one patient).
15. STAT — Lilly's confirmation that it was reviewing more requests (August 3, 2026; accessible opening includes the company's statement).
16. Ro — Weight-loss program pricing, free insurance coverage checker, insurance support and exclusions, Terms of Use, section 16.
17. CMS — Medicare GLP-1 Bridge: information for providers.
18. CDC — Calculating BMI (June 18, 2024; formula only, not a medical eligibility determination).
19. National Capital Poison Center — Poison Control help and emergency guidance.

Corrections: found an error? Email hello@therxindex.com so our editorial team can review it.